Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2019

View Archived Issues

Molecular subtyping identifies problematic lung nodules

Fusion protein hVEGF121-M2-GnRH3-hinge-MVP is immunogenic and inhibits prostate tumor growth in mice

AN-12855: improved efficacy and resistance potential vs. isoniazid in M. tuberculosis mouse model

Mayo Clinic initiates phase I study of AR-160 in relapsed or refractory B-cell NHL

Phase I study of Sc-rAAV2.5IL-1Ra in moderate knee OA now enrolling participants

Data from phase IIb study of inhaled alprazolam for acute seizure rescue treatment reported at AAN

Creston presents CRS-0540 for treating infections with resistant Gram-positive pathogens

NIAID initiates phase I study of a trispecific broadly neutralizing antibody against HIV

Cialis returns to Viagra's roots

ALY-688 shows efficacy in atropine-induced rabbit model of dry eye disease

KR-67607 shows potential as neuroprotective therapeutic agent for glaucoma

TOP-1257, a potent inhibitor of inflammation and angiogenesis

Prion may be answer to Alzheimer's amyloid riddle

Preclinical data support development of AB-2004 for GI dysfunction in autism spectrum disorder

First-in-human data presented for PBT-434 alpha-synuclein aggregation inhibitor

Syros Pharmaceuticals identifies new tyrosine-protein kinase inhibitors

Genentech and Roche present RIPK1 inhibitors

Ramot at Tel Aviv University discloses compounds for neuropathic pain

AbbVie initiates phase III study of ABBV-951 in Parkinson's disease

FDA approves Kadcyla for adjuvant treatment in HER2-positive early breast cancer setting

Shanxi Medical University patents EMSCs for cardiovascular diseases

Preliminary data from OLE study of Liproca depot suggest longer treatment intervals

SK Bioscience synthesizes compounds for RSV infections

Preliminary data from phase I study of Oraxol in angiosarcoma show complete responses

High rates of remission seen with KTE-X19 in young patients with B-cell acute lymphoblastic leukemia

Novel potent mGlu7 negative allosteric modulator with high CNS penetration and favorable properties

Kazia reports safety data from phase IIa study of GDC-0084 in newly diagnosed glioblastoma

Connect Biopharma reports phase I data and new study in atopic dermatitis with CBP-201

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...